Replies to post #120417 on Anavex Life Sciences Corp (AVXL)

[tredenwater2]

Nidan is it possible that Biogen is in the mix helping to design a trial for MS under this new protocol as well. Could they do multiple endpoints allowing them to mix a small percentage of their top drug (currently the SOC) for MS? Has anyone heard a smidget of info on the latest conference that mentioned MS?

The plot thickens!

Tred

[Gernee20]

Yes exactly.

I was more thinking that if the 3 trials show relief in all indications, we might be looking at approval most quickly for Rett, but being we designed 3 trials cohesively with the FDA in an attempt to stack evidence that 2-73 is restoring homeostasis, the FDA will allow compassionate use for not only all 3 indications, but possibly for untested indications? This obviously is driven by 2-73 remaining extremely safe throughout the trials. I wonder if the FDA, for any reason would want the trials all starting about the same time which could cause delay to Rett?If In fact there is a master protocol for 2-73 and the 3 trials, I'm sure if all indications all show similar symptom relief at the same week on the drug, this could also help approval. Not saying the trials need or will start the same day, but starting all of them within s 4-6 weeks of one another makes sense imo.